Clinical Trial Update: Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial of the complement inhibitor eculizumab in adolescent patients with plasma therapy–sensitive atypical hemolytic uremic syndrome has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2015-01-26